Age related macular degeneration
|
0.400 |
Biomarker
|
disease |
BEFREE |
Anti-vascular endothelial growth factor (anti-VEGF) proteins are the gold-standard treatment for posterior eye segment proliferative vascular diseases such as Age-Related Macular Degeneration (AMD) and Diabetic Retinopathy (DR).
|
31436780 |
2019 |
Age related macular degeneration
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our study thus provides a potential mechanism underlying the association of the VEGFA locus with AMD.
|
31080113 |
2019 |
Age related macular degeneration
|
0.400 |
Biomarker
|
disease |
BEFREE |
Currently approved therapies for age-related macular degeneration (AMD) are inhibitors against vascular endothelial growth factor (VEGF), which is a major contributor to the pathogenesis of neovascular AMD (nAMD).
|
31454678 |
2019 |
Age related macular degeneration
|
0.400 |
Biomarker
|
disease |
BEFREE |
Anti-vascular endothelial growth factor agents have been widely used to treat several eye diseases including age-related macular degeneration (AMD).
|
31399890 |
2019 |
Age related macular degeneration
|
0.400 |
Biomarker
|
disease |
BEFREE |
Among genetic variables, SNPs of CFH, ARMS2, IL-8, TIMP3, SLC16A8, RAD51B, VEGFA and COL8A1 were significantly associated with the risk of AMD in the Italian cohort.
|
29197628 |
2018 |
Age related macular degeneration
|
0.400 |
Biomarker
|
disease |
BEFREE |
Intravitreal injection of vascular endothelial growth factor (VEGF) inhibitor is the most effective therapy for AMD.
|
29367644 |
2018 |
Age related macular degeneration
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Mechanical stress occurs during different stages of AMD and is a possible inducer of VEGF expression in RPE cells.
|
30328441 |
2018 |
Age related macular degeneration
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To identify disease-specific cytokine profile differences in the aqueous humor (AH) (other than the vascular endothelial growth factor) between patients with dry and treated wet age-related macular degeneration (AMD) and healthy controls.
|
30157273 |
2018 |
Age related macular degeneration
|
0.400 |
Biomarker
|
disease |
BEFREE |
The standard-of-care therapeutics for the treatment of ocular neovascular diseases like wet age-related macular degeneration (AMD) are biologics targeting vascular endothelial growth factor signaling.
|
29193961 |
2018 |
Age related macular degeneration
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Vascular endothelial growth factor (VEGF) expression induces age-related macular degeneration (AMD), which is a common vision-threatening disease due to choroidal neovascularization and a fibrovascular membrane.
|
30200369 |
2018 |
Age related macular degeneration
|
0.400 |
Biomarker
|
disease |
BEFREE |
Vascular endothelial growth factor (VEGF) is a key component in the development and progression of wet AMD.
|
29446046 |
2018 |
Age related macular degeneration
|
0.400 |
Biomarker
|
disease |
BEFREE |
Overall, 224 anti-VEGF naïve subjects including 56 patients in early AMD group, 56 patients in intermediate AMD group, 56 patients in neovascular AMD group and 56 patients in no AMD group were recruited.
|
30594908 |
2018 |
Age related macular degeneration
|
0.400 |
Biomarker
|
disease |
BEFREE |
CD36 gene is associated with intraocular pressure elevation after intravitreal application of anti-VEGF agents in patients with age-related macular degeneration: Implications for the safety of the therapy.
|
28557591 |
2018 |
Age related macular degeneration
|
0.400 |
Biomarker
|
disease |
BEFREE |
PROGRESSION OF MACULAR ATROPHY IN EYES WITH TYPE 1 NEOVASCULARIZATION AND AGE-RELATED MACULAR DEGENERATION RECEIVING LONG-TERM INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY: An Optical Coherence Tomographic Angiography Analysis.
|
28723848 |
2018 |
Age related macular degeneration
|
0.400 |
Biomarker
|
disease |
BEFREE |
The results shown in this study pave the way for the development of a personalized gene therapy strategy for the treatment of wet AMD that is substantially less invasive and more clinically adaptable than the current treatment paradigm of repetitive bolus injections of anti-VEGF agents.
|
30082848 |
2018 |
Age related macular degeneration
|
0.400 |
Biomarker
|
disease |
BEFREE |
Anti-vascular endothelial growth factor agents effectively treat age-related macular degeneration and myopic choroidal neovascularization (CNV).
|
29533953 |
2018 |
Age related macular degeneration
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The single nucleotide polymorphism genotyping showed that TT genotype for MMP-9 -1702T/A and CC genotype for VEGF +936C/T increase markedly the risk of age-related macular degeneration but do not influence on its progression.
|
30289322 |
2018 |
Age related macular degeneration
|
0.400 |
Biomarker
|
disease |
BEFREE |
Four weeks after the first injection, VEGF in the patients with AMD had dropped significantly (P < 0.001).
|
28151839 |
2018 |
Age related macular degeneration
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
PLEKHA1 958A/G polymorphism was associated with a decreased AMD risk (additive model: aOR=0.722, 95% CI=0.450-0.979, P=0.019; allele model: aOR=0.883, 95% CI=0.736-0.992, P=0.014), while all other polymorphisms were associated with an increased AMD risk (CX3CR1 839C/T, additive model: aOR=2.682, 95% CI=1.119-5.709, P=0.022, recessive model: aOR=2.729, 95% CI=1.141-6.048, P=0.010; CX3CR1 745G/A, additive model: aOR=2.614, 95% CI=1.231-6.012, P=0.020, recessive model: aOR=2.340, 95% CI=1.227-5.993, P=0.011; VEGFA +674C/T, additive model: aOR=1.601, 95% CI=1.253-2.179, P<0.001, dominant model: aOR=1.287, 95% CI=1.058-1.570, P<0.001, allele model: OR=1.220, 95% CI=1.118-1.427, P<0.001; VEGFA +936C/T, additive model: aOR=1.509, 95% CI=1.105-2.311, P<0.001, recessive model: aOR=1.432, 95% CI=1.027-2.192, P=0.009, dominant model: aOR=1.207, 95% CI=1.031-1.514, P0.001, allele model: aOR=1.216, 95% CI=1.062-1.408, P<0.001).
|
29565837 |
2018 |
Age related macular degeneration
|
0.400 |
Biomarker
|
disease |
BEFREE |
As a result of intensive studies on VEGF pathobiology, anti-VEGF strategy has become a major therapeutics for wet AMD and DR. To investigate the potential impact of anti-VEGF strategy on major retinal supporting cells, Müller glia (MG), we disrupted VEGF receptor-2 (VEGFR2) in MG with conditional knockout (CKO) and examined the effect of VEGFR2-null on MG viability and neuronal integrity in mice.
|
29721978 |
2018 |
Age related macular degeneration
|
0.400 |
Biomarker
|
disease |
BEFREE |
Clinicopathologic Correlation of Anti-Vascular Endothelial Growth Factor-Treated Type 3 Neovascularization in Age-Related Macular Degeneration.
|
28964579 |
2018 |
Age related macular degeneration
|
0.400 |
Biomarker
|
disease |
BEFREE |
Conbercept is a novel vascular endothelial growth factor (VEGF) inhibitor for the treatment of wet age-related macular degeneration (AMD).
|
29902977 |
2018 |
Age related macular degeneration
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Large trials on anti-VEGF/PDGF (vascular endothelial/platelet-derived growth factor) combination therapy have been established to improve management of neovascular activity in age-related macular degeneration.
|
29721663 |
2018 |
Age related macular degeneration
|
0.400 |
Biomarker
|
disease |
BEFREE |
Abicipar-pegol (abicipar), a DARPin molecule targeting vascular endothelial growth factor-A (VEGF-A), is currently under evaluation in patients with age-related macular degeneration.
|
30535424 |
2018 |
Age related macular degeneration
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Taken together, these findings exhibit a proangiogenic role for TBK1 via upregulating the expression of VEGF, and may suggest that TBK1 inhibition offers a unique and alternative method for prevention and treatment of AMD.
|
29864423 |
2018 |